The drug binds to TGF, EGFR, FGF, PDGF, and IGF causing impaired growth of cell and is used for breast cancer treatment. In combination with paclitaxel, it is effective and non-cytotoxic in metastatic breast cancer at 10 and 50 μmol/l concentrations in phase I and II trials. The gene discussed is EGFR; the disease is breast carcinoma.